Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

WILLIAM A GREISNER

Allopathic & Osteopathic Physicians Allergy & Immunology

NPI
1720095334
CMS profile
259552
Location
LEXINGTON, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$14,404.31

134 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

WILLIAM A GREISNER

NPI 1720095334 · CMS profile ID 259552

Allopathic & Osteopathic Physicians / Allergy & Immunology

LEXINGTON, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1720095334?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
WILLIAM A GREISNER, NPI 1720095334, CMS profile ID 259552. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1720095334?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). WILLIAM A GREISNER, NPI 1720095334, CMS profile ID 259552. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1720095334?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
WILLIAM A GREISNER, NPI 1720095334, CMS profile ID 259552, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1720095334?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

134 matching records · $14,404.31 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 134 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–134 of 134.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ARS Pharmaceuticals Operations, Inc. $18.4803/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1245876204 CMS
Grifols USA, LLC $26.9603/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249543759 CMS
Regeneron Healthcare Solutions, Inc. $106.7403/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212932723 CMS
Blueprint Medicines Corporation $14.6203/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235824259 CMS
CSL Behring $12.5803/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232382048 CMS
GENZYME CORPORATION $8.7503/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233279054 CMS
Organon LLC $32.5403/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1237762846 CMS
GENZYME CORPORATION $60.6803/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233279090 CMS
GENZYME CORPORATION $60.6803/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233279092 CMS
kaleo, Inc. $41.5203/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240100474 CMS
AstraZeneca Pharmaceuticals LP $90.0903/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1214791147 CMS
AstraZeneca Pharmaceuticals LP $113.4203/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1215333212 CMS
GENZYME CORPORATION $92.5003/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233279062 CMS
GENZYME CORPORATION $28.4303/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233279072 CMS
Genentech, Inc. $64.5003/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211607587 CMS
Blueprint Medicines Corporation $37.2402/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235824257 CMS
Genentech USA, Inc. $87.1602/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211607557 CMS
Genentech USA, Inc. $144.1702/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211607561 CMS
Lilly USA, LLC $35.3802/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186989298 CMS
Lilly USA, LLC $12.3102/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1187050923 CMS
Lilly USA, LLC $25.2702/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1187050925 CMS
CSL Behring $31.8302/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232382042 CMS
PFIZER INC. $19.2302/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231381396 CMS
Optinose US, Inc. $22.3802/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1163253272 CMS
Cycle Pharmaceuticals Inc $28.8502/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248902367 CMS
CSL Behring $28.4402/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232382038 CMS
kaleo, Inc. $1,000.0001/30/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1240100480 CMS
kaleo, Inc. $94.9601/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240100472 CMS
AstraZeneca Pharmaceuticals LP $136.1101/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1214770824 CMS
GENZYME CORPORATION $114.7201/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233279058 CMS
kaleo, Inc. $1,000.0001/09/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1240100476 CMS
GENZYME CORPORATION $46.2701/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233279040 CMS
kaleo, Inc. $1,000.0001/08/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1240100478 CMS
ARS Pharmaceuticals Operations, Inc. $25.0501/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1245876202 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,384.49 67
PY2020 $1,859.75 65
PY2021 $2,403.42 103
PY2022 $2,755.27 121
PY2023 $5,530.94 118
PY2024 $8,001.13 93
PY2025 $14,404.31 134

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $265,608.56 37
PY2024 Principal investigator $306,474.85 35
PY2023 Principal investigator $431,332.11 50
PY2022 Principal investigator $304,278.58 60
PY2021 Principal investigator $160,229.56 37
PY2020 Principal investigator $95,780.23 3
PY2019 Principal investigator $197,779.47 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

37 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,359.28 12/24/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA ASSOCIATES PSC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184280306
Principal investigator 1 GlaxoSmithKline, LLC. $25,955.10 12/23/2025 Non-covered Recipient Entity
BLUEGRASS ALLERGY CARE
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192147196
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $215.05 12/19/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA ASSOCIATES PSC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184278760
Principal investigator 1 GlaxoSmithKline, LLC. $12,595.50 11/25/2025 Non-covered Recipient Entity
BLUEGRASS ALLERGY CARE
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192181820
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $215.05 11/19/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA ASSOCIATES PSC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184262179
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,325.57 10/17/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA ASSOCIATES PSC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184251185
Principal investigator 1 GlaxoSmithKline, LLC. $1,395.30 10/02/2025 Non-covered Recipient Entity
BLUEGRASS ALLERGY CARE
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192181815
Principal investigator 1 GlaxoSmithKline, LLC. $3,722.01 09/18/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192147182
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,298.53 09/15/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA ASSOCIATES PSC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184237002
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $215.05 09/15/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA ASSOCIATES PSC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184237004
Principal investigator 1 AstraZeneca UK Limited $13,783.65 08/20/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA ASSOCIATES PSC
a phase two a,randomized,double blind,placebo controlled study to assess efficacy and safety of atuliflapon given orally once daily for twelve weeks in adults with moderate to severe uncontrolled asthma No dispute reported 06/30/2026 1185539765
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $215.05 08/20/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA ASSOCIATES PSC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184228895
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,264.81 08/20/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA ASSOCIATES PSC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184228909
Principal investigator 1 GlaxoSmithKline, LLC. $1,158.21 08/01/2025 Non-covered Recipient Entity
BLUEGRASS ALLERGY CARE
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192147199
Principal investigator 1 GlaxoSmithKline, LLC. $2,232.00 08/01/2025 Non-covered Recipient Entity
BLUEGRASS ALLERGY CARE
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192181811
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,315.00 07/29/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA ASSOCIATES PSC
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 1185539759
Principal investigator 1 GlaxoSmithKline, LLC. $6,409.26 07/22/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192147192
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,593.72 07/14/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA ASSOCIATES PSC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184214936
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,821.23 07/14/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA ASSOCIATES PSC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184214938
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $590.49 06/27/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA ASSOCIATES PSC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184211717
Principal investigator 1 GlaxoSmithKline, LLC. $243.00 05/02/2025 Non-covered Recipient Entity
BLUEGRASS ALLERGY CARE
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192181823
Principal investigator 1 GlaxoSmithKline, LLC. $9,828.18 04/24/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192147187
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $30,915.00 04/24/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA ASSOCIATES PSC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244047542
Principal investigator 1 GlaxoSmithKline, LLC. $477.00 04/11/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA ASSOCIATES PSC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192143447
Principal investigator 1 GlaxoSmithKline, LLC. $1,380.00 04/11/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA ASSOCIATES PSC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192143450
Principal investigator 1 GlaxoSmithKline, LLC. $650.00 04/11/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA ASSOCIATES PSC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192147179
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,831.00 04/09/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA ASSOCIATES PSC
A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 1185539761
Principal investigator 1 GlaxoSmithKline, LLC. $790.00 04/02/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA ASSOCIATES PSC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192143455
Principal investigator 1 GlaxoSmithKline, LLC. $756.00 04/02/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA ASSOCIATES PSC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192143459
Principal investigator 1 GlaxoSmithKline, LLC. $2,370.00 04/02/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA ASSOCIATES PSC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192143463
Principal investigator 1 GlaxoSmithKline, LLC. $1,288.00 04/02/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA ASSOCIATES PSC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192147172
Principal investigator 1 GlaxoSmithKline, LLC. $2,385.00 04/02/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA ASSOCIATES PSC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192147176
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $204.60 03/06/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA ASSOCIATES PSC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244047574
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,679.06 02/24/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA ASSOCIATES PSC
A Multicenter,Single arm,Open label,Post Authorization,Phase 4 Effectiveness and Safety Study of Tezepelumab in Adult and Adolescent Participants with Severe Asthma including Several Under Studied Populations in the United States No dispute reported 06/30/2026 1185539755
Principal investigator 1 Eli Lilly and Company $83,723.34 01/15/2025 Non-covered Recipient Entity
MERCY HEALTH - LOURDES HOSPITAL LLC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB/ LY3650150 IN ADULT PARTICIPANTS WITH PERENNIAL ALLERGIC RHINITIS No dispute reported 06/30/2026 1187886096
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,200.00 01/03/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA ASSOCIATES PSC
A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma No dispute reported 06/30/2026 1185539757
Principal investigator 1 AstraZeneca Pharmaceuticals LP $33,208.52 01/03/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA ASSOCIATES PSC
The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic corticosteroid or monoclonal antibod No dispute reported 06/30/2026 1185539763